A conserved metabolic signature associated with response to fast-acting anti-malarial agents

Microbiol Spectr. 2023 Dec 12;11(6):e0397622. doi: 10.1128/spectrum.03976-22. Epub 2023 Oct 6.

Abstract

In malaria drug discovery, understanding the mode of action of lead compounds is important as it helps in predicting the potential emergence of drug resistance in the field when these drugs are eventually deployed. In this study, we have employed metabolomics technologies to characterize the potential targets of anti-malarial drug candidates in the developmental pipeline at NITD. We show that NITD fast-acting leads belonging to spiroindolone and imidazothiadiazole class induce a common biochemical theme in drug-exposed malaria parasites which is similar to another fast-acting, clinically available drug, DHA. These biochemical features which are absent in a slower acting NITD lead (GNF17) point to hemoglobin digestion and inhibition of the pyrimidine pathway as potential action points for these drugs. These biochemical themes can be used to identify and inform on the mode of action of fast drug candidates of similar profiles in future drug discovery programs.

Keywords: Plasmodium falciparum; anti-malarial agents; malaria; metabolomics.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Drug Discovery
  • Drug Resistance
  • Humans
  • Malaria*
  • Malaria, Falciparum* / drug therapy
  • Plasmodium falciparum

Substances

  • Antimalarials
  • imidazothiadiazole